| Having trouble viewing this email? Click here |
![]() |
||||||
| Advancing and protecting our clients' interests in the pharmacy benefit marketplace for more than 20 years. | ||||||
|
SUMMARY OF TOP ARTICLES - MAY 15, 2014
Osteoporosis Drugs' Long-Term Use Needs More Research: FDA HealthDay News - May 13, 2014 The long-term risks and benefits of taking bisphosphonates, a class of drugs widely used for osteoporosis, require more research, according to the U.S. Food and Drug Administration. First Million-Dollar Drug Near After Prices Double on Dozens of Treatments Bloomberg - April 30, 2014 Earl Harford, a retired professor, recently bought a month’s worth of the pills he needs to keep his leukemia at bay. The cost: $7,676, or three times more than when he first began taking the pills in 2001. Over the years, he has paid more than $140,000 from his retirement savings to cover his share of the drug’s price. Pictures on prescriptions help illiterate patients take medicines correctly Medical News Today - May 8, 2014 Using pictures and symbols, rather than handwritten words, on prescriptions helps illiterate patients take their medicines correctly when they leave hospital, say doctors today. CVS/pharmacy applies for new URAC accreditation for community pharmacies Drug Store News - May 6, 2014 URAC, a national accreditation company, has launched a new accreditation program, Community Pharmacy, and CVS/pharmacy has stepped forward to be the first applicant organization to seek community pharmacy accreditation from URAC. Lilly's diabetes drug better than Sanofi's in late-stage trials Reuters - May 12, 2014 Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials. Medicare Struggling With Hepatitis-C Cure Costs Kaiser Health News - May 12, 2014 Researchers estimate that 3 to 5 million Americans carry the insidious hep-C virus. The biggest concentration is among those born between 1945 and 1965. Study: Flu vaccines prevent hospitalizations in seniors, even when vaccine effectiveness is low Drug Store News - May 12, 2014 A new study from the Centers for Disease Control and Prevention found that flu vaccines prevent flu-associated hospitalizations in people 65 years and older, even during seasons when vaccine effectiveness is low, the agency stated Friday. Advocates seek to curb patient bills for specialty drugs KPCC - March 00, 2014 Patient and provider advocacy groups are accusing California’s health insurance companies of discriminating against people with certain diseases by requiring them to pay more for their medications. Breakthrough Cancer Drugs Inflate Treatment Costs Drug Discovery & Development - May 6, 2014 Astronomical prices for breakthrough new cancer drugs are pushing up treatment costs for patients as well as insurers, making it tougher for patients to complete lengthy therapy at a time when it's increasingly effective. Tadalafil, Sildenafil Promising in Duchenne Muscular Dystrophy Drug Discovery & Development - May 8, 2014 Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children. ADHD medicine’s long-term safety still a question Reuters - May 2, 2014 Scant research has been done on the long-term safety of drugs for attention-deficit/hyperactivity disorder (ADHD), a new analysis shows, though millions of American children have been taking them for decades. Wasteful services cost Medicare up to $8.5 billion, study estimates Modern Healthcare - May 12, 2014 One in four Medicare patients got medical care at least once in 2009 that provided no benefit at a total cost of at least $1.9 billion, newly published research suggests. Contact, Kristin LaVitola Marketing Director, PSG Pharmaceutical Strategies Group (PSG) Office: 972-244-8388 Email: KLavitola@PSGConsults.com PSGNewsletter@PSGConsults.com www.PSGConsults.com |
|||||